KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

Core Insights - Merck announced significant results showing that the combination of KEYTRUDA® (pembrolizumab) and Padcev® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 60% and the risk of death by 50% when administered before and after radical cystectomy compared to surgery alone in patients with muscle-invasive bladder cancer (MIBC) [1] Group 1 - The combination therapy demonstrated a 60% reduction in the risk of event-free survival (EFS) events [1] - The therapy also resulted in a 50% reduction in the risk of death [1] - The study focused on patients with muscle-invasive bladder cancer (MIBC) who are not eligible for standard treatment [1]